KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Shares Outstanding (Diluted Average): 2013-2025

Historic Shares Outstanding (Diluted Average) for Travere Therapeutics (TVTX) over the last 11 years, with Sep 2025 value amounting to $102.6 million.

  • Travere Therapeutics' Shares Outstanding (Diluted Average) rose 31.94% to $102.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.6 million, marking a year-over-year increase of 31.94%. This contributed to the annual value of $78.9 million for FY2024, which is 6.22% up from last year.
  • Travere Therapeutics' Shares Outstanding (Diluted Average) amounted to $102.6 million in Q3 2025, which was up 15.37% from $88.9 million recorded in Q2 2025.
  • Travere Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $102.6 million for Q3 2025, and its period low was $56.3 million during Q1 2021.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $80.5 million, with a median of $77.5 million in 2024.
  • Data for Travere Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY surged of 35.31% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Travere Therapeutics' Shares Outstanding (Diluted Average) stood at $59.8 million in 2021, then climbed by 6.56% to $63.8 million in 2022, then climbed by 16.48% to $74.3 million in 2023, then climbed by 6.22% to $78.9 million in 2024, then surged by 31.94% to $102.6 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $102.6 million in Q3 2025, compared to $88.9 million in Q2 2025 and $88.4 million in Q1 2025.